Genmab — December 2016
-
Ofatumumab Monotherapy Active in Waldenström Macroglobulinemia http://www.cancertherapyadvisor.com/hematologic-cancers/waldenstrom-macroglobulinemia-ofatumumab-monotherapy-active-treatment/article/576754/
-
The findings suggest that ofatumumab monotherapy should be a novel non-chemotherapeutic strategy for patients with Waldenström macroglobulinemia, particularly those with high IgM concentrations
-
Det er en sjældent familiemedlem af Non Hodgkin.
-
men
-
Positivt, men et meget lille datagrundlag.
-
Det gør firmaerne heller ikke.
-
Det er først og fremmest en fagmands konference med uddybning af data og behandlingsstrategier.
-
Det kan der sagtens, men det er først og fremmest myndighedsgodkendelser og markedsføring- og salgstilladelser som kan betragtes som reelt kursdrivende. Gode data er "fugle på taget".
-
Den slags kan markedet sagtens reagere på.
-
Netop.
-
spændende dage omkring ASH. Genmab sørger virkelig at gøre sig lækker for allerede eksisterende eller kommende investorer.
-
God morgen.
-
Tak.. ilm
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind